63
Participants
Start Date
October 31, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
C2L-OCT-01 PR 30 mg
Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
Republican Centre for Medical Rehabilitation and Water-therapy, Minsk
Semmelweis Egyetem Altalanos Orvostudomanyi, Budapest
"Institue of Endocrinology C.I Parhon Bucharest", Bucharest
Institute of Endocrinology, University Clinical Center, Belgrade
Fakultna Nemocnica s Poliklinkow Bratislava, Bratislava
V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine, Kiev
Lead Sponsor
Ambrilia Biopharma, Inc.
INDUSTRY